Avoid anticholinergics in Parkinson’s, say researchers, despite study findings Use of anticholinergic drugs by patients with newly diagnosed Parkinson’s disease is not associated with cognitive decline, according to new research.…
Cancer drug shows promise for Parkinson’s disease Patients with Parkinson’s disease were given the leukaemia drug nilotinib, which improved symptoms of the disease.…
Placebos: more than meets the eye Often dismissed as fakes, placebos seem to work on the same brain pathways targeted by ‘real’ treatments and involve a complex network of genes.…
Antimalaria drugs could be an effective treatment for Parkinson’s disease Two antimalarials were found to activate a receptor in the brain that is involved in protecting neurons that are lost in Parkinson’s disease.…
Clinical Pharmacist’s monthly news round-up: the top 10 in the past month What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month.…
Psychiatric drugs can affect moral decisions about willingness to harm Commonly prescribed psychiatric drugs can influence moral decisions about self-harm or inflicting harm on others, according to new research.…
Review collates evidence on increased risk of death for anticholinergics A new systematic review and meta-analysis suggests that patients using any drug with anticholinergic effects have a 45% increased risk of cognitive impairment.…
Welsh pharmacies offer Parkinson’s MURs in awareness campaign Patients with Parkinson’s disease offered medicines advice and support at pharmacies in Wales.…
Obtaining consent from patients is not always straightforward How do you obtain consent when the patient is unable to give it?…
Creatine does not slow progression in Parkinson’s disease, study finds Five years of creatine at a dose of 10mg/day does not slow disease progression in patients with early, stable Parkinson’s disease, a study published in JAMA shows.…
